OpenAI has introduced GPT-Rosalind, a frontier reasoning model designed to accelerate life sciences research and drug discovery workflows. The model combines improved tool use with deeper understanding across chemistry, protein engineering, and genomics to help researchers navigate complex scientific processes. Named after Rosalind Franklin, whose work revealed DNA's structure, GPT-Rosalind aims to compress the typical 10-15 year drug development timeline by enhancing early-stage discovery.

Built for modern scientific work, the model excels at reasoning over molecules, proteins, genes, and disease-relevant biology. OpenAI reports that GPT-Rosalind outperforms GPT-5.4 on six out of eleven research tasks in the LABBench2 benchmark, with notable gains in molecular cloning protocol design. The company partnered with Dyno Therapeutics to evaluate the model on RNA sequence-to-function prediction, where submissions ranked above the 95th percentile of human experts.

GPT-Rosalind is now available through OpenAI's trusted access program for qualified enterprise customers, with a freely accessible Life Sciences research plugin for Codex connecting to over 50 scientific tools and databases. The company is collaborating with organizations including Amgen, Moderna, and Thermo Fisher Scientific to apply the model across research workflows, from evidence synthesis to experimental planning.